Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics
This presentation reviews Axiomer editing oligonucleotides (EONs) structure activity, the potential of Axiomer platform as well as its applicability for the treatment of liver originated disorders.
What is RNA and how can we use the body's own RNA editing machinery to treat disease? Learn more about the Axiomer® RNA editing technology and how we are creating a new class of medicines.
ProQR invented an entirely new way to treat genetic diseases. Axiomer enables RNA base editing by recruiting ADAR so your own body can treat disease. Learn more here.
… Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … which is related to targeted RNA editing using endogenous ADARs and is part of ProQR’s intellectual property estate …
… Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … granted patent JP 7244922 , which is related to the broad concept of using chemically modified oligonucleotides …
